Exelixis Presents at 2025 Wells Fargo Healthcare Conference: Key Takeaways and Insights

Exelixis, a commercial-stage biotech company, is presenting at the 2025 Wells Fargo Healthcare Conference. The company's CEO, Michael Morrissey, will discuss the state of the business, including its focus on oncology and its lead drug, cabozantinib, which is used to treat kidney cancer. Morrissey will also address potential risks and forward-looking statements.

Exelixis, Inc. (NASDAQ: EXEL) has announced the appointment of Dana T. Aftab, Ph.D., as its Executive Vice President, Research and Development. Dr. Aftab, who has been with the company for over 25 years, will oversee all aspects of Exelixis' drug discovery, translational research, product development, and medical affairs activities [1].

Dr. Aftab has a deep expertise that spans the drug discovery and development continuum. He has been a key contributor to many of Exelixis' most important milestones, including the discovery, development, and introduction of cabozantinib, which he and the broader Exelixis team grew from an initial orphan drug indication into a global oncology franchise [1].

In his new role, Dr. Aftab will lead Exelixis' wide-ranging product development organization as the team maximizes the opportunities for its portfolio. This includes cabozantinib, zanzalintinib, a third-generation oral tyrosine kinase inhibitor currently in multiple pivotal trials, and an earlier stage pipeline of promising small molecules and biotherapeutics [1].

Exelixis' CEO, Michael M. Morrissey, Ph.D., said, "Dana is an excellent choice to lead our product development organization as we continue to maximize the opportunities for our portfolio" [1].

The appointment comes as Exelixis prepares to present at the 2025 Wells Fargo Healthcare Conference, where CEO Morrissey will discuss the state of the business, its focus on oncology, and its lead drug, cabozantinib, which is used to treat kidney cancer. Morrissey will also address potential risks and forward-looking statements [1].

References:
[1] https://www.marketscreener.com/news/exelixis-announces-appointment-of-dana-t-aftab-ph-d-as-executive-vice-president-research-and-dev-ce7c50d2d18df323
[2] https://finance.yahoo.com/news/exelixis-inc-exel-halts-phase-085127677.html
[3] https://www.morningstar.com/news/business-wire/20250829389096/exelixis-announces-appointment-of-dana-t-aftab-phd-as-executive-vice-president-research-and-development